Brief: Cognition Therapeutics Study Of Zervimesine (Ct1812) In Early Alzheimer’S Disease Reaches 75% Enrollment Target
03/09/2025 15:22
Sept 3 (Reuters) - Cognition Therapeutics Inc CGTX.O: COGNITION THERAPEUTICS STUDY OF ZERVIMESINE (CT1812) IN EARLY ALZHEIMER’S DISEASE REACHES 75% ENROLLMENT TARGET Source text: ID:nGNX90RxV8 Further company coverage: CGTX.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Cognition Therapeutics
See all newsU.S. STOCKS ON THE MOVE-Quest Diagnostics, Tractor Supply, Dutch Bros
U.S. STOCKS ON THE MOVE-CME, Lockheed Martin, Valero Energy
Cognition rises after FDA backs late-stage trial plan for dementia drug
Brief: Cognition Therapeutics Announces Issuance Of Composition Of Matter Patent, Extending Protection For Zervimesine (CT1812) Through 2045
Brief: Cognition Therapeutics Schedules A Type C Meeting With FDA To Align On Endpoints For Phase 3 Trial Of Zervimesine (Ct1812) In DLB